Research
Hormonal
Excessive nitric oxide production, particularly via inducible NOS (iNOS) during inflammation, is cytotoxic, promotes oxidative stress, and impairs mitochondrial function, leading to cell death and organ failure.
While NO is beneficial in normal amounts, chronic inflammation can lead to excessive NO production that damages cells. Managing inflammation through lifestyle and medical care helps prevent this harmful excess.
ModerateRefutesMEDIUM confidence
Very high NO levels, generated upon inflammatory iNOS induction, compete with O2, engendering NO-dependent hypoxia (‘nitroxia’)... NO/RNS can then shut down mitochondrial respiration at multiple sites by irreversibly inhibiting ETC complexes at the expense of ATP production, with cytotoxic effect.
Why this rating
Review paper describing pathological mechanisms.
Source
Characterization of the Role of Nitric Oxide and Its Clinical Applications
Arlene B. Levine et al. · Cardiology · 2012
DOI 10.1159/000338150
narrative_reviewCited 263×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Physiologic levels of nitric oxide (NO) enhance insulin sensitivity and glucose uptake in skeletal muscle by improving microvascular perfusion and directly blocking inhibitory interactions with insulin signaling pathways.Moderate
- Physiologic levels of nitric oxide reduce mitochondrial oxidative stress and ROS production by lowering mitochondrial membrane potential, thereby protecting against cellular aging and oxidative damage.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →